Fibromyalgia is a disorder characterized by widespread muscle pain, which is often accompanied by mood issues, memory problems, sleep disturbances and fatigue. Some patients also experience cognitive difficulties and physical exhaustion.
Now Israel plans to recognize the disorder as a disability, with the country’s Welfare and Social Affairs announcing in October that individuals suffering from the disorder will be recognized as disabled in a couple of weeks, which will allow them to claim disability allowance. This move will make Israel among the first nations around the globe to make provisions for patients with this condition.
Data from the Israeli Fibromyalgia Association and the country’s health ministry suggests that about 240,000 individuals, which make up about 4% of the country’s population, are afflicted with this disorder and its sibling ailment, chronic fatigue syndrome.
An increase in fibromyalgia cases has been observed in communities near the Gaza border, with many believing that the disorder may be triggered by trauma. Individuals with the condition have often complained that because physical symptoms don’t show up in scans and blood tests, authorities don’t financially support them; physicians seldom take their disorders seriously as well. However, over the last 10 years, the condition’s existence has become more widely accepted among medical professionals.
In a statement, the National Insurance Institute of Israel stated that the reason the condition wasn’t widely recognized was the fact that most clinicians believed that fibromyalgia was a mental disability. The institute further asserted that it was against this belief, noting that after a professional examination by doctors in the institute, the Pension Division and the Legal Bureau, it had determined that there was cause to include the condition on the existing list of disorders that are eligible for social security allowances.
In a separate interview with the Times of Israel, the Bar Ilan University’s director of the Disability Rights Clinic, Roni Rothler, stated that patients with fibromyalgia had struggled to have the condition recognized by the relevant authorities, noting that this progress would enable them to take better care of themselves using the disability stipends. This will also improve their quality of life, which will assist people with these conditions, most of whom can’t follow a normal work routine.
In addition to this, Rothler asserted that this recognition was crucial with regard to gender politics, as the condition predominantly affects women. Data from the National Institutes of Health in the United States supports this claim, showing that almost 90% of all cases are diagnosed in women. Men are also known to get milder and fewer symptoms in comparison with women.
In the United States, about 4 million individuals are afflicted by fibromyalgia, and it is good that several companies, such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are devoting resources to the search for effective treatments for this debilitating condition.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
